Summaries & Highlights

11990 views 1275 hours watched
17:12

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Long-Term Survival Outcomes in Advanced Melanoma - Insights From CheckMate 067, KEYNOTE-006, and ImmunoCobiVem Trials

FEATURING Jessica Hassel
  • 12 views
  • November 6, 2024
13:57

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Optimal Sequencing of Therapeutic Strategies in Immunogenic mCRC

FEATURING Thierry André
  • 23 views
  • November 5, 2024
18:22

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Sequencing CRC Targeted Therapies Based on Biomarkers and Biology

FEATURING Lukas Weiss
  • 42 views
  • November 4, 2024
20:07

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Developmental Therapeutics Highlights

FEATURING Guru Sonpavde
  • 251 views
  • October 25, 2024
  • 3
20:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Breast12, CAPItello-290, and ICARUS-BREAST01

FEATURING Sara Tolaney, Hope Rugo
  • 517 views
  • October 4, 2024
  • 6
03:33

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Advances, Wins, and Challenges

FEATURING Mansoor Raza Mirza
  • 327 views
  • September 20, 2024
  • 4
13:05

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in HCC

FEATURING Richard Kim, Tiago Biachi
  • 195 views
  • October 21, 2024
  • 2
22:19

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancreatic Cancer

FEATURING Davide Melisi
  • 221 views
  • October 17, 2024
  • 3
13:46

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Systemic Treatment for ILCs in Breast Cancer

FEATURING Jens Huober
  • 313 views
  • October 17, 2024
  • 2
38:49

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE

FEATURING Sara Tolaney, Hope Rugo
  • 514 views
  • October 4, 2024
  • 4
12:48

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Practice-Shaping Prostate Cancer Trials

FEATURING Eleni Efstathiou
  • 83 views
  • October 15, 2024
09:54

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Practice

FEATURING Hani Babiker
  • 251 views
  • October 14, 2024
  • 1
05:16

ecancer

ESMO 2024 Insights: ROME Basket Trial - Targeting Actionable Mutations vs. SoC in Pts With Advanced Solid Tumors

FEATURING Andrea Botticelli
  • 15 views
  • October 22, 2024
24:59

ecancer

ESMO 2024: Latest in Bladder Cancer - Expert Review

FEATURING Patrizia Giannatempo, Andrea Necchi, Simon Crabb, Michiel Simon Van Der Heijden
  • 27 views
  • October 22, 2024
24:24

ecancer

ESMO 2024 Summary: Highlights & Analysis of the Biggest Solid Cancer Updates

FEATURING Bishal Gyawali
  • 37 views
  • October 21, 2024
14:52

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01

FEATURING Paolo Tarantino
  • 720 views
  • September 24, 2024
  • 4
14:02

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in CRC and Impacts on Practice

FEATURING Richard Kim, Tiago Biachi
  • 180 views
  • October 21, 2024
  • 3
17:44

ecancer

ESMO 2024: Optimizing the Personalization of Prostate Cancer Treatment

FEATURING Alison Birtle, Alejo RodríGuez-Vida, Pasquale Rescigno, Gunhild von Amsberg
  • 43 views
  • October 22, 2024
14:28

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Updates in HCC and Impacts on Practice

FEATURING Hani Babiker
  • 151 views
  • October 14, 2024
  • 1
18:44

ecancer

ESMO 2024 Summary: Understanding the Use of PARPi Combinations to Treat Patients With mCRPC

FEATURING Axel Merseburger, Friederike Schlürmann, Elena Castro, Gerhardt Attard
  • 23 views
  • October 11, 2024
18:36

ecancer

ESMO 2024 Summary: Latest Updates in mRCC

FEATURING Javier Puente, Guillermo de Velasco, Cristina Suárez, Stéphane Oudard
  • 41 views
  • October 11, 2024
19:15

ecancer

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON, REZILIENT1, LAURA, and SKIPPirr

FEATURING Ignacio Gil-Bazo, Mariana Brandão, Benjamin Besse, Enriqueta Felip
  • 218 views
  • October 11, 2024
08:54

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mCRPC) and NIAGARA (MIBC)

FEATURING Robert Dreicer
  • 275 views
  • September 24, 2024
  • 2
14:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in Heme Malignancies

FEATURING Maria Gomes da Silva
  • 419 views
  • September 23, 2024
  • 2
20:09

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC

FEATURING Lorenza Rimassa
  • 367 views
  • September 20, 2024
  • 4
07:40

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR

FEATURING Petros Grivas
  • 245 views
  • September 20, 2024
  • 1
13:27

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Head & Neck Cancer Highlights

FEATURING Nabil Saba
  • 303 views
  • September 23, 2024
  • 3
15:55

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Bladder and RCC Highlights

FEATURING Karine Tawagi, Natalie Reizine
  • 108 views
  • October 10, 2024
16:28

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights of Radioligand Therapies in Prostate Cancer

FEATURING Natalie Reizine, Karine Tawagi
  • 75 views
  • October 10, 2024
  • 1
11:54

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients With Bone Metastases

FEATURING Robbe Van den Begin
  • 331 views
  • September 26, 2024
  • 5
17:20

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights of Important Trials in Sarcoma

FEATURING Robin Jones
  • 179 views
  • October 9, 2024
18:24

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Neoadjuvant Immunotherapy as the Future of Melanoma Treatment - Identifying Patients Who Need Surgery

FEATURING Alexander van Akkooi
  • 56 views
  • October 9, 2024
14:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Novel Agents and Promising Combinations in mRCC and mUC

FEATURING Begoña Pérez-Valderrama
  • 59 views
  • October 8, 2024
08:52

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Managing Durable Responses and De-Escalation Strategies in Urothelial Cancer With Systemic Therapy

FEATURING Debbie Robbrecht
  • 23 views
  • October 8, 2024
11:58

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Tailoring Therapy in TNBC and Beyond

FEATURING Lisa Carey
  • 351 views
  • October 8, 2024
  • 4
17:24

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Updates in the Treatment of MCL

FEATURING Georg Hess
  • 221 views
  • September 27, 2024
05:38

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New Therapeutic Approaches in Gynecologic Cancers

FEATURING Susana Banerjee
  • 79 views
  • October 8, 2024
22:06

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Head & Neck Cancer Take Home Messages

FEATURING Paolo Bossi
  • 309 views
  • October 8, 2024
  • 5
18:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Discussing Key Studies on the Use of Zipalertinib, Zidesamtinib, and PM8002/BNT327 With CT in NSCLC

FEATURING Joop Langen
  • 75 views
  • October 7, 2024
  • 2
20:00

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Optimizing Precision Therapy in HR+/HER2- Advanced Breast Cancer Post-Endocrine + CDK4/6i

FEATURING Philippe Aftimos
  • 190 views
  • October 7, 2024
16:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Liquid Biopsies in GI Cancers - Learnings From Colorectal Cancer

FEATURING Naureen Starling
  • 175 views
  • October 7, 2024
04:40

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clinical and Translational Advances

FEATURING Julien Taieb
  • 290 views
  • October 6, 2024
  • 1
10:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Predicting the Outcomes of Advanced Cutaneous Melanoma Cases Following Discontinuation of Immune Checkpoint Inhibition

FEATURING Ka-Won Noh, Oana Diana Persa
  • 65 views
  • October 3, 2024
08:09

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Optimizing Curative Opportunities in Early HCC

FEATURING Stephen L. Chan
  • 103 views
  • October 2, 2024
  • 1
16:14

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC), and CheckMate 9ER (aRCC)

FEATURING Camillo Porta
  • 174 views
  • October 2, 2024
  • 3
16:26

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Evaluation of Ivonescimab + CT and PM8002/BNT327 + Nab-Paclitaxel for 1L TNBC: Results From Two Studies

FEATURING Carmen Criscitiello
  • 154 views
  • October 1, 2024
09:33

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Metastatic Melanoma Highlights

FEATURING Christian Blank
  • 197 views
  • September 25, 2024
14:19

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

FEATURING Howard Hochster
  • 397 views
  • September 23, 2024
  • 4
06:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and Other Updates

FEATURING Elizabeth R. Plimack
  • 173 views
  • September 27, 2024
  • 3
20:25

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in mBC

FEATURING Giampaolo Bianchini
  • 463 views
  • October 1, 2024
  • 7
29:24

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Breast Cancer Highlights - AURORA Program, DAISY Trial, DESTINY-Breast06 Study, and Targeted Therapy Sequencing

FEATURING Christos Sotiriou
  • 466 views
  • October 1, 2024
  • 4
07:07

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm

FEATURING Teresa Macarulla Mercade
  • 45 views
  • September 30, 2024
07:53

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: IDH Mutated Cholangiocarcinoma - Diagnostic and Treatment Paradigm

FEATURING Teresa Macarulla Mercade
  • 37 views
  • September 30, 2024
15:44

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Primary CNS Lymphoma - Updated ESMO and EHA Guidelines

FEATURING Andres Ferreri
  • 80 views
  • September 30, 2024
05:57

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: ctDNA and Molecular Screening for Target Detection and Treatment Monitoring in mBC

FEATURING Michail Ignatiadis
  • 121 views
  • September 26, 2024
09:12

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290

FEATURING Virginia Kaklamani
  • 477 views
  • September 23, 2024
  • 7
20:07

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment

FEATURING Guru Sonpavde
  • 154 views
  • September 24, 2024
05:13

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Advances in Cervical Cancer Management - Comprehensive Strategies for Recurrent or Metastatic Disease

FEATURING Domenica Lorusso
  • 201 views
  • September 23, 2024
12:17

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

FEATURING Douglas Johnson
  • 178 views
  • September 25, 2024
13:14

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: The Latest Data on NMIBC and Localized MIBC

FEATURING Félix Guerrero-Ramos
  • 54 views
  • September 25, 2024
14:58

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Bladder Cancer Highlights - JCOG1019, TOMBOLA, and SunRISe-4

FEATURING Bogdana Schmidt
  • 115 views
  • September 23, 2024
  • 2

Breast

6977 views 717 hours watched
09:23

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-Year Outcomes From the NATALEE Trial

FEATURING Peter Fasching
  • 7 views
  • November 19, 2024
05:07

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Residual Cancer Burden & Adjuvant Capecitabine in Early TNBC With Non-pCR

FEATURING Sung-Bae Kim
  • 20 views
  • November 15, 2024
  • 1
04:06

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: TroFuse-010 Trial - Sacituzumab Tirumotecan ± Pembro vs. Chemo in HR+/HER2- Advanced BC

FEATURING Sara Tolaney
  • 215 views
  • November 4, 2024
  • 2
05:58

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Long-Term Outcomes and Treatment Strategies by ER Expression in Breast Cancer

FEATURING Kazuki Nozawa
  • 78 views
  • October 29, 2024
09:29

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Outcomes in HR+/HER2- eBC by Prior Systemic Therapy - Insights From the NATALEE Trial Subgroup Analysis

FEATURING Nicholas McAndrew
  • 197 views
  • October 25, 2024
38:49

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE

FEATURING Sara Tolaney, Hope Rugo
  • 514 views
  • October 4, 2024
  • 4
20:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Breast12, CAPItello-290, and ICARUS-BREAST01

FEATURING Sara Tolaney, Hope Rugo
  • 517 views
  • October 4, 2024
  • 6
09:12

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290

FEATURING Virginia Kaklamani
  • 477 views
  • September 23, 2024
  • 7
14:52

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01

FEATURING Paolo Tarantino
  • 720 views
  • September 24, 2024
  • 4
29:24

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Breast Cancer Highlights - AURORA Program, DAISY Trial, DESTINY-Breast06 Study, and Targeted Therapy Sequencing

FEATURING Christos Sotiriou
  • 466 views
  • October 1, 2024
  • 4
11:58

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Tailoring Therapy in TNBC and Beyond

FEATURING Lisa Carey
  • 351 views
  • October 8, 2024
  • 4
20:25

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in mBC

FEATURING Giampaolo Bianchini
  • 463 views
  • October 1, 2024
  • 7
13:46

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Systemic Treatment for ILCs in Breast Cancer

FEATURING Jens Huober
  • 313 views
  • October 17, 2024
  • 2
20:00

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Optimizing Precision Therapy in HR+/HER2- Advanced Breast Cancer Post-Endocrine + CDK4/6i

FEATURING Philippe Aftimos
  • 190 views
  • October 7, 2024
05:57

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: ctDNA and Molecular Screening for Target Detection and Treatment Monitoring in mBC

FEATURING Michail Ignatiadis
  • 121 views
  • September 26, 2024
16:26

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Evaluation of Ivonescimab + CT and PM8002/BNT327 + Nab-Paclitaxel for 1L TNBC: Results From Two Studies

FEATURING Carmen Criscitiello
  • 154 views
  • October 1, 2024
04:16

ecancer

ESMO 2024 Insights: Neo-CheckRay Trial - Durvalumab & Oleclumab Boost for SBRT + Chemo in ER+/HER2- eBC

FEATURING Alex De Caluwe
  • 13 views
  • October 11, 2024
05:58

ecancer

ESMO 2024 Insights: WSG-TP-II Trial - ET + Trastuzumab & Pertuzumab vs. De-Escalated Chemo + Trastuzumab & Pertuzumab in HR+/HER2+ eBC

FEATURING Oleg Gluz
  • 42 views
  • October 11, 2024
  • 1
05:05

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Real-World Evidence of Recurrence Risk in Node- and Node+ HR+/HER2- eBC From US Electronic Health Records

FEATURING Komal Jhaveri
  • 170 views
  • October 17, 2024
  • 3
04:09

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Ovarian Function Suppression in HR+ HER2+ Breast Cancer - Exploratory Analysis From HERA Trial

FEATURING Sung Gwe Ahn
  • 40 views
  • October 8, 2024
10:17

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: T-DXd in HER2+ mBC With or Without Brain Metastases - DESTINYBreast-12 Primary Results

FEATURING Nancy Lin
  • 201 views
  • October 8, 2024
  • 1
07:25

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: DESTINY-Breast04 - Exploratory Biomarker Analysis of T-DXd vs. Physician’s Choice in HR+/HER2- mBC

FEATURING Naoto Ueno
  • 231 views
  • October 9, 2024
  • 1
08:20

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: A Registry-Based Study of pCR & Survival After Neoadjuvant Chemo in Stage I TNBC

FEATURING Manon De Graaf
  • 41 views
  • October 1, 2024
11:09

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: TRIPLE-B Study - 1L Carboplatin-Cyclophosphamide vs. Paclitaxel +/- Atezolizumab for mTNBC

FEATURING Rosie Voorthuis
  • 47 views
  • October 1, 2024
02:25

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Quantitative High Sensitivity HER2 Testing With Trastuzumab Deruxtecan in mBC

FEATURING Paolo Tarantino
  • 223 views
  • October 1, 2024
  • 3
02:49

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Real-World Characteristics of NATALEE and monarchE Eligible Populations - A US Electronic Health Records Analysis

FEATURING Paolo Tarantino
  • 176 views
  • September 27, 2024
  • 2
11:05

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC

FEATURING Giuseppe Viale
  • 323 views
  • September 23, 2024
  • 2
09:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: CAPItello-290 Trial - Capivasertib + Paclitaxel as 1L Treatment for mTNBC

FEATURING Heather McArthur
  • 134 views
  • September 24, 2024
  • 1
06:37

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Pembro or Placebo + CT in High-Risk Early TNBC - OS Results From KEYNOTE-522

FEATURING Heather McArthur
  • 155 views
  • September 24, 2024
  • 2
06:18

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Prognostic Role of TILs on OS and Treatment De-Escalation in HER2+ Early BC in the ShortHER Trial

FEATURING Maria Vittoria Dieci
  • 104 views
  • September 19, 2024
04:26

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: DETECT V trial - Omission of Chemo and Addition of the CDK4/6i Ribociclib in HER2+ and HR+ mBC

FEATURING Wolfgang Janni
  • 31 views
  • September 23, 2024
04:30

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: PROMENADE Trial - Pembro for Early ER-Low/HER2- BC - Real World French Cohort

FEATURING Francois Cherifi
  • 85 views
  • September 23, 2024
  • 2
14:39

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Hypo vs. Normofractionated RT in eBC - 5-Year Results of HypoG-01

FEATURING Sofia Rivera
  • 156 views
  • September 20, 2024

GI

4161 views 364 hours watched
13:22

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Efficacy of 177Lu-DOTA-TATE in GEP-NETs - Multivariate Analysis of NETTER-2 Study

FEATURING Diego Ferone
  • 4 views
  • November 13, 2024
13:57

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Optimal Sequencing of Therapeutic Strategies in Immunogenic mCRC

FEATURING Thierry André
  • 23 views
  • November 5, 2024
18:22

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Sequencing CRC Targeted Therapies Based on Biomarkers and Biology

FEATURING Lukas Weiss
  • 42 views
  • November 4, 2024
14:19

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

FEATURING Howard Hochster
  • 397 views
  • September 23, 2024
  • 4
04:40

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clinical and Translational Advances

FEATURING Julien Taieb
  • 290 views
  • October 6, 2024
  • 1
20:09

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC

FEATURING Lorenza Rimassa
  • 367 views
  • September 20, 2024
  • 4
13:05

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in HCC

FEATURING Richard Kim, Tiago Biachi
  • 195 views
  • October 21, 2024
  • 2
14:02

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in CRC and Impacts on Practice

FEATURING Richard Kim, Tiago Biachi
  • 180 views
  • October 21, 2024
  • 3
22:19

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancreatic Cancer

FEATURING Davide Melisi
  • 221 views
  • October 17, 2024
  • 3
09:54

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Practice

FEATURING Hani Babiker
  • 251 views
  • October 14, 2024
  • 1
14:28

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Updates in HCC and Impacts on Practice

FEATURING Hani Babiker
  • 151 views
  • October 14, 2024
  • 1
16:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Liquid Biopsies in GI Cancers - Learnings From Colorectal Cancer

FEATURING Naureen Starling
  • 175 views
  • October 7, 2024
08:09

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Optimizing Curative Opportunities in Early HCC

FEATURING Stephen L. Chan
  • 103 views
  • October 2, 2024
  • 1
15:22

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cancer - Nature vs. Nurture

FEATURING Shuji Ogino
  • 261 views
  • October 1, 2024
  • 1
07:07

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm

FEATURING Teresa Macarulla Mercade
  • 45 views
  • September 30, 2024
10:31

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Treatment Strategies and Sequencing in Carcinoid Syndrome

FEATURING Rachel Riechelmann
  • 101 views
  • September 24, 2024
  • 3
04:15

ecancer

ESMO 2024 Insights: NO-CUT Trial - Total Neoadjuvant Treatment Without Surgery for Locally Advanced Rectal Cancer

FEATURING Alessio Amatu
  • 169 views
  • October 14, 2024
05:16

ecancer

ESMO 2024 Insights: ROME Basket Trial - Targeting Actionable Mutations vs. SoC in Pts With Advanced Solid Tumors

FEATURING Andrea Botticelli
  • 15 views
  • October 22, 2024
05:40

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: CheckMate 9DW Expanded Analysis - Nivo + Ipi vs. Len or Sorafenib in 1L Unresectable HCC

FEATURING Hatim Karachiwala
  • 131 views
  • October 21, 2024
  • 1
09:14

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Machine Learning-Based Prediction of Lymph Node Metastasis in Early Gastric Cancer

FEATURING Weiyao Li
  • 13 views
  • October 21, 2024
09:23

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: The Value of Immune Checkpoint Blockade in MSS/pMMR mCRC

FEATURING Benjamin Geisler
  • 128 views
  • October 8, 2024
04:42

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: EPOC2001 Study - Lenvatinib + Pembro + FLOT in Neoadjuvant/Adjuvant Treatment for Gastric and GEJ Adenocarcinoma

FEATURING Akihito Kawazoe
  • 150 views
  • October 3, 2024
13:50

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: DESTINY-Gastric03 - T-DXd Monotherapy and Combinations in Pts With Adv/Metastatic HER2+ Esophageal, Gastric, or GEJ Adenocarcinoma

FEATURING Yelena Janjigian
  • 125 views
  • October 2, 2024
  • 1
09:56

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvalumab in Unresectable HCC

FEATURING Lorenza Rimassa
  • 168 views
  • September 20, 2024
02:14

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Nal-IRI/LV5-FU vs. Paclitaxel as 2L Therapy in Metastatic Esophageal SCC - OESIRI-PRODIGE 62 Study

FEATURING David Tougeron
  • 62 views
  • September 27, 2024
06:55

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Fruquintinib in Refractory mCRC - Subgroup Analysis of the FRESCO-2 Trial

FEATURING Rocio Garcia-Carbonero
  • 51 views
  • October 1, 2024
14:03

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: POD1UM-303/InterAACT 2 - Retifanlimab + C-P in Untreated Inoperable or Metastatic Anal Squamous Cell Carcinoma

FEATURING Sheela Rao
  • 65 views
  • September 27, 2024
  • 1
03:57

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Pembro + CAPOX + Bevacizumab in MSS mCRC With High Immune Infiltrate - FFCD 1703 POCHI Trial

FEATURING David Tougeron
  • 82 views
  • September 27, 2024
  • 1
04:39

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - Ph3 LEAP-012 Study

FEATURING Josep Llovet
  • 196 views
  • September 23, 2024
  • 1

GU

3480 views 241 hours watched
20:07

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Developmental Therapeutics Highlights

FEATURING Guru Sonpavde
  • 251 views
  • October 25, 2024
  • 3
07:40

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR

FEATURING Petros Grivas
  • 245 views
  • September 20, 2024
  • 1
06:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and Other Updates

FEATURING Elizabeth R. Plimack
  • 173 views
  • September 27, 2024
  • 3
20:07

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment

FEATURING Guru Sonpavde
  • 154 views
  • September 24, 2024
08:54

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mCRPC) and NIAGARA (MIBC)

FEATURING Robert Dreicer
  • 275 views
  • September 24, 2024
  • 2
17:44

ecancer

ESMO 2024: Optimizing the Personalization of Prostate Cancer Treatment

FEATURING Alison Birtle, Alejo RodríGuez-Vida, Pasquale Rescigno, Gunhild von Amsberg
  • 43 views
  • October 22, 2024
24:59

ecancer

ESMO 2024: Latest in Bladder Cancer - Expert Review

FEATURING Patrizia Giannatempo, Andrea Necchi, Simon Crabb, Michiel Simon Van Der Heijden
  • 27 views
  • October 22, 2024
12:48

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Practice-Shaping Prostate Cancer Trials

FEATURING Eleni Efstathiou
  • 83 views
  • October 15, 2024
18:44

ecancer

ESMO 2024 Summary: Understanding the Use of PARPi Combinations to Treat Patients With mCRPC

FEATURING Axel Merseburger, Friederike Schlürmann, Elena Castro, Gerhardt Attard
  • 23 views
  • October 11, 2024
18:36

ecancer

ESMO 2024 Summary: Latest Updates in mRCC

FEATURING Javier Puente, Guillermo de Velasco, Cristina Suárez, Stéphane Oudard
  • 41 views
  • October 11, 2024
15:55

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Bladder and RCC Highlights

FEATURING Karine Tawagi, Natalie Reizine
  • 108 views
  • October 10, 2024
14:58

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Bladder Cancer Highlights - JCOG1019, TOMBOLA, and SunRISe-4

FEATURING Bogdana Schmidt
  • 115 views
  • September 23, 2024
  • 2
13:14

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: The Latest Data on NMIBC and Localized MIBC

FEATURING Félix Guerrero-Ramos
  • 54 views
  • September 25, 2024
16:14

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC), and CheckMate 9ER (aRCC)

FEATURING Camillo Porta
  • 174 views
  • October 2, 2024
  • 3
16:28

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights of Radioligand Therapies in Prostate Cancer

FEATURING Natalie Reizine, Karine Tawagi
  • 75 views
  • October 10, 2024
  • 1
14:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Novel Agents and Promising Combinations in mRCC and mUC

FEATURING Begoña Pérez-Valderrama
  • 59 views
  • October 8, 2024
08:52

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Managing Durable Responses and De-Escalation Strategies in Urothelial Cancer With Systemic Therapy

FEATURING Debbie Robbrecht
  • 23 views
  • October 8, 2024
05:32

ecancer

ESMO 2024 Insights: PEACE-3 Trial - Enzalutamide Treatment Boosted by Radium-223 in mCRPC

FEATURING Silke Gillessen
  • 56 views
  • October 11, 2024
12:33

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: SWOG-1216 Trial - Inherited Variants in SRD5A Genes & Response to Hormonal Therapy in Prostate Cancer

FEATURING Jacek Pinski
  • 31 views
  • October 11, 2024
04:08

ecancer

ESMO 2024 Insights: SUNNIFORECAST Trial - Nivo + Ipi vs. Standard of Care in Non-Clear-Cell RCCs

FEATURING Lothar Bergmann
  • 10 views
  • October 16, 2024
04:45

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Baseline Radiological Tumor Burden and Outcomes in mccRCC Treated With 1L IO-Based Regimens

FEATURING Rashad Nawfal
  • 13 views
  • October 17, 2024
04:19

ecancer

ESMO 2024 Insights: JCOG1019 Study - Watchful Waiting vs. Intravesical BCG in HGT1 Bladder Cancer

FEATURING Hiroshi Kitamura
  • 23 views
  • October 16, 2024
  • 1
21:42

ecancer

ESMO 2024 Insights: Best Practice in HRRm Testing in Patients With Metastatic Prostate Cancer

FEATURING Karim Fizazi, Anders Bjartell, Niven Mehra, Eleni Efstathiou
  • 92 views
  • October 16, 2024
07:15

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Circulating Tumor Cell Enumeration and OS in mCRPC Treated With Xaluritamig

FEATURING Andrew Armstrong
  • 30 views
  • October 14, 2024
10:22

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Glycoproteomic Biomarkers as Predictors of NIVO+CABO vs. Sunitinib Response in aRCC - CheckMate 9ER

FEATURING David Braun
  • 82 views
  • October 17, 2024
  • 1
07:21

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Safety & Activity of First-in-Class Dual AR Degrader & Antagonist BMS-986365 in Heavily Pretreated mCRPC Patients

FEATURING Andrew Armstrong
  • 24 views
  • October 16, 2024
07:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: 1L EV + Pembro in Cis-Ineligible la/mUC - 5-Year Follow-Up of Study EV-103 DE/A

FEATURING Jonathan Rosenberg
  • 44 views
  • October 10, 2024
09:31

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: JCOG1019 Phase 3 Study Comparing the Effectiveness of Watchful Waiting & Intravesical BCG in Pts With HGT1 Bladder Cancer With pT0 on the 2nd Transurethral Resection Specimen

FEATURING Hiroshi Kitamura
  • 3 views
  • October 10, 2024
07:53

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Futibatinib + Pembro in Advanced/Metastatic Urothelial Carcinoma - Final Analysis of Efficacy and Safety

FEATURING Vadim Koshkin
  • 59 views
  • October 8, 2024
12:19

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Response Evaluation Using ctDNA and PET Imaging in mCRPC Treated With LuPSMA + Pembro - PRINCE Trial

FEATURING Sofie Tolmeijer
  • 110 views
  • October 4, 2024
  • 2
04:04

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan vs. Everolimus in Patients With Previously Treated Advanced ccRCC

FEATURING Brian Rini
  • 94 views
  • September 25, 2024
10:51

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: STAMPEDE2 Comparison P - Upfront Accelerated 177Lu-PSMA-617 in mHSPC

FEATURING Minal Padden-Modi, Nick James
  • 66 views
  • September 25, 2024
  • 1
06:33

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation vs. Placebo in Patients Receiving Pembro + Axitinib for mRCC

FEATURING Chiara Ciccarese
  • 154 views
  • September 24, 2024
  • 2
10:52

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: ORACLE Study - Outcomes With Novel Combination Therapies in Non-Clear Cell RCC

FEATURING Deepak Kilari
  • 15 views
  • October 1, 2024
07:45

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: INSPIRE Trial - Nivolumab and Ipilimumab in Molecularly Selected mCRPC Patients

FEATURING Niven Mehra
  • 118 views
  • October 1, 2024
  • 1
06:24

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: SG + EV as ≥ 2L Therapy for mUC - Updated Efficacy Profile of the Double Antibody Drug Conjugate Trial

FEATURING Bradley McGregor
  • 63 views
  • October 1, 2024
27:15

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Multi-Gene Copy Number Variation Risk-Score for Predicting Survival and Therapy Response in Treatment-Naïve mCRPC

FEATURING Manish Kohli
  • 17 views
  • October 1, 2024
04:57

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: EMBARK Study Post-Hoc Analysis By Age - Enzalutamide +/- Leuprolide in Patients With High-Risk Biochemically Recurrent Prostate Cancer

FEATURING Neal Shore
  • 58 views
  • September 27, 2024
14:11

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: RAPSON Study - Radium223-Docetaxel vs. Docetaxel-Radium223 Sequence in mCRPC with Prospective Biomarker Evaluation

FEATURING Vincenza Conteduca
  • 22 views
  • September 25, 2024
11:54

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT

FEATURING Hoda Abdel-Aty
  • 101 views
  • September 24, 2024
06:06

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: PEACE-1 Trial - Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer

FEATURING Cedric Pobel
  • 27 views
  • September 24, 2024
04:40

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: VOLGA Trial - ctDNA Clearance in Cisplatin-Ineligible MIBC With Durvalumab + Tremelimumab + Enfortumab Vedotin

FEATURING Alexandra Drakaki
  • 51 views
  • September 23, 2024
03:55

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: SOGUG-AUREA Study - Split-Dose Cisplatin and Atezolizumab in Cisplatin-Ineligible Urothelial Carcinoma

FEATURING Guillermo de Velasco
  • 56 views
  • September 23, 2024
  • 1
05:54

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Predictive Tumor Suppressor Gene Signature for Early Progression in mHSPC

FEATURING Marta Garcia De Herreros
  • 24 views
  • September 20, 2024
06:55

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC - Ph3 CheckMate 67T

FEATURING Laurence Albiges
  • 114 views
  • September 19, 2024
  • 1

GYN

2333 views 162 hours watched
05:38

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New Therapeutic Approaches in Gynecologic Cancers

FEATURING Susana Banerjee
  • 79 views
  • October 8, 2024
03:33

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Advances, Wins, and Challenges

FEATURING Mansoor Raza Mirza
  • 327 views
  • September 20, 2024
  • 4
05:13

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Advances in Cervical Cancer Management - Comprehensive Strategies for Recurrent or Metastatic Disease

FEATURING Domenica Lorusso
  • 201 views
  • September 23, 2024
08:52

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Advanced Ovarian Cancer - PRIMA Trial

FEATURING Bradley J. Monk
  • 441 views
  • September 19, 2024
  • 4
13:14

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagnosed Ovarian Cancer - ATHENA-COMBO Ph3 Trial

FEATURING Bradley J. Monk
  • 258 views
  • September 19, 2024
  • 1
06:35

ecancer

ESMO 2024 Insights: Novel ADC TORL-1-23 in Heavily-Pretreated Ovarian, Endometrial, and Testicular Cancers

FEATURING Gottfried Konecny
  • 41 views
  • October 14, 2024
06:02

ecancer

ESMO 2024 Insights: PRIMA Trial - Newly Diagnosed Advanced Ovarian Cancer Treated With Niraparib for 1L Maintenance

FEATURING Antonio González-Martín
  • 137 views
  • October 14, 2024
  • 1
06:17

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Dose Optimization of Gotistobart + Pembro in Platinum-Resistant Ovarian Cancer - PRESERVE-004/GOG-3081 Study

FEATURING Joyce Barlin
  • 37 views
  • October 16, 2024
06:42

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: HER2 Expression and Its Relationship to HRD Status and Biomarkers in Ovarian Cancer

FEATURING Dahye Lee
  • 56 views
  • October 16, 2024
07:51

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Mirvetuximab Soravtansine-gynx (MIRV) in Platinum-Sensitive Ovarian Cancer With High FRα - PICCOLO Trial Results

FEATURING Angeles Secord
  • 123 views
  • October 1, 2024
  • 4
04:55

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Stereotactic RT Alone or Followed by Niraparib for OMD or OPD in Ovarian Cancer Following PARPi Therapy - SOPRANO Trial

FEATURING Susana Banerjee
  • 45 views
  • October 7, 2024
02:36

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Risk Factors for Recurrence and Prognostic Subgroups in Stage I Uterine Leiomyosarcomas - Insights From the Daydream Study

FEATURING Alejandro Gallego
  • 31 views
  • October 1, 2024
09:02

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Induction Chemo Followed by CRT in Advanced Cervical Cancer - QoL Outcomes From GCIG INTERLACE

FEATURING Gemma Eminowicz
  • 69 views
  • September 27, 2024
11:46

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Pembro or Placebo in Combination With Adjuvant Chemo +/- RT in Pts With Newly Diagnosed, High-Risk Endometrial Cancer From ENGOT-EN11/GOG-3053/KEYNOTE-B21

FEATURING Brian Slomovitz
  • 220 views
  • September 26, 2024
  • 3
04:11

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Final OS From the ATALANTE/ENGOT-ov29 Trial Evaluating Atz vs. Placebo With Standard Cx + Bev in Ovarian Cancer Patients With Platinum-Sensitive Relapse

FEATURING Jean-Emmanuel Kurtz
  • 30 views
  • September 26, 2024
08:11

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Clinical and Molecular Predictors of Outcome in Patients With Tubo-Ovarian High-Grade Serous Carcinoma and Exceptional Survival

FEATURING Tibor A. Zwimpfer
  • 65 views
  • September 25, 2024
13:20

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: OS Results for Pembro + CRT for High-Risk Locally Advanced Cervical Cancer - ENGOT-cx11/GOG-3047/KEYNOTE-A18

FEATURING Domenica Lorusso
  • 173 views
  • September 23, 2024
  • 2

Lung

2008 views 135 hours watched
19:15

ecancer

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON, REZILIENT1, LAURA, and SKIPPirr

FEATURING Ignacio Gil-Bazo, Mariana Brandão, Benjamin Besse, Enriqueta Felip
  • 218 views
  • October 11, 2024
18:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Discussing Key Studies on the Use of Zipalertinib, Zidesamtinib, and PM8002/BNT327 With CT in NSCLC

FEATURING Joop Langen
  • 75 views
  • October 7, 2024
  • 2
11:54

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients With Bone Metastases

FEATURING Robbe Van den Begin
  • 331 views
  • September 26, 2024
  • 5
08:49

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-Deruxtecan Related ILD - A Real-World Experience

FEATURING Kelsey Natsuhara
  • 731 views
  • October 14, 2024
  • 3
11:14

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: CCTG BR.31 - Adjuvant Durvalumab in Completely Resected NSCLC

FEATURING Glenwood Goss
  • 18 views
  • October 21, 2024
07:10

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: LBA51 DUART Trial - ctDNA Dynamics and Treatment Responses in CT-Ineligible Stage III NSCLC

FEATURING Andrea Filippi
  • 11 views
  • October 11, 2024
05:10

ecancer

ESMO 2024 Insights: PIONeeR Trial - IO Resistance Pathways Investigated to Tailor Combination Advanced NSCLC Therapy

FEATURING Pascale Tomasini
  • 24 views
  • October 11, 2024
06:35

ecancer

ESMO 2024 Insights: Canadian Cancer Trials Group BR.31 Study - Adjuvant Durvalumab After Complete Tumor Resection & Optional Chemo in Early Stage (IB-IIIA) NSCLC

FEATURING Glenwood Goss
  • 24 views
  • October 11, 2024
13:59

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: EP0031 - Next-Generation RET Inhibitor Correlating Molecular and Clinical Responses in RET-Altered Solid Tumors

FEATURING Elena Garralda
  • 37 views
  • October 11, 2024
  • 1
07:02

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: ARROS-1 Study - Zidesamtinib in Advanced ROS1 Fusion-Positive NSCLC and Other Solid Tumors

FEATURING Benjamin Besse
  • 37 views
  • October 1, 2024
09:10

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Acquired Resistance to 1L Amivantamab + Lazertinib vs. Osimertinib in EGFR-Mutant aNSCLC - Early MARIPOSA Study Analysis

FEATURING Benjamin Besse
  • 119 views
  • October 1, 2024
16:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: IBI354 - Anti-HER2 ADC in Advanced Solid Tumors and Breast Cancer

FEATURING Christina Teng
  • 67 views
  • October 1, 2024
  • 2
04:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: RELATIVITY-104 Study - Nivo + Relatlimab With Platinum-Doublet Chemo vs. Nivo + Platinum-Doublet Chemo as 1L Treatment for Stage IV or Recurrent NSCLC

FEATURING Nicolas Girard
  • 135 views
  • September 18, 2024
  • 1
10:50

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Emerging Molecular Targets in Thymic Epithelial Tumors

FEATURING Anja Roden
  • 44 views
  • September 26, 2024
18:46

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Current and Future Use of EGFR-Targeted Agents in Lung Cancer

FEATURING Pilar Garrido
  • 137 views
  • September 26, 2024
  • 1

Head & Neck

1206 views 94 hours watched
22:06

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Head & Neck Cancer Take Home Messages

FEATURING Paolo Bossi
  • 309 views
  • October 8, 2024
  • 5
13:27

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Head & Neck Cancer Highlights

FEATURING Nabil Saba
  • 303 views
  • September 23, 2024
  • 3
04:46

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: 3-Weekly vs. Weekly Cisplatin in High-Risk HNSCC Post-Op CRT - Final Results of JCOG1008

FEATURING Makoto Tahara
  • 178 views
  • September 20, 2024
08:17

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Avelumab-Cetuximab-RT vs. SoC in Locally Advanced HNSCC - Final Analysis From the REACH Trial

FEATURING Makoto Tahara
  • 134 views
  • September 20, 2024
08:59

ecancer

ESMO 2024 Insights: EA3163 Trial - Chemo Followed by Surgery & PORT vs. Surgery & PORT for Organ Preservation of T3 & T4a (Selected T4b) Sinonasal Squamous Cell Carcinoma

FEATURING Nabil Saba
  • 23 views
  • October 14, 2024
07:52

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: TACTI-003 - Eftilagimod Alpha + Pembro vs. Pembro Alone in 1L Recurrent/Metastatic HNSCC

FEATURING Hisham Mehanna
  • 17 views
  • October 14, 2024
12:42

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Sequential vs. Induction CT With Concurrent CRT for Locoregionally Advanced Nasopharyngeal Carcinoma

FEATURING Hisham Mehanna
  • 37 views
  • October 14, 2024
13:21

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Neoadjuvant Chemo Followed by Surgery & Post-Operative RT vs. Surgery & Post-Operative RT for Organ Preservation of T3 & T4a Nasal and Paranasal Sinus SCC

FEATURING Nabil Saba
  • 58 views
  • September 23, 2024
  • 1
07:11

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: GORTEC 2017-01 REACH Trial - Avelumab-Cetuximab-RT vs. Standards of Care in Patients With Locally Advanced SCC of Head & Neck

FEATURING Yungan Tao
  • 58 views
  • September 23, 2024
06:00

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Setanaxib + Pembro in Recurrent or Metastatic HNSCC

FEATURING Makoto Tahara
  • 89 views
  • September 20, 2024

Skin

838 views 78 hours watched
17:12

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Long-Term Survival Outcomes in Advanced Melanoma - Insights From CheckMate 067, KEYNOTE-006, and ImmunoCobiVem Trials

FEATURING Jessica Hassel
  • 12 views
  • November 6, 2024
08:45

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Follow-Up Brain Imaging in Melanoma Patients With Brain Metastasis After ICI

FEATURING Imren Ozdamar
  • 13 views
  • November 4, 2024
18:24

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Neoadjuvant Immunotherapy as the Future of Melanoma Treatment - Identifying Patients Who Need Surgery

FEATURING Alexander van Akkooi
  • 56 views
  • October 9, 2024
12:17

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

FEATURING Douglas Johnson
  • 178 views
  • September 25, 2024
09:33

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Metastatic Melanoma Highlights

FEATURING Christian Blank
  • 197 views
  • September 25, 2024
10:40

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Survival Impact of Adjuvant Treatment in Stage III Melanoma

FEATURING Hildur Helgadottir
  • 104 views
  • September 20, 2024
10:42

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Distant Metastasis-Free Survival in Neoadjuvant vs. Adjuvant Nivo for Stage III Melanoma - The NADINA Trial

FEATURING Alexander van Akkooi
  • 14 views
  • October 22, 2024
05:23

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Biomarker Analysis and Outcomes in Neoadjuvant Nivo + Relatlimab for Resectable Melanoma

FEATURING Liz Burton
  • 24 views
  • October 17, 2024
06:14

ecancer

ESMO 2024 Insights: NADINA Trial - Neoadjuvant Ipi Added to Nivo in Resectable Advanced Melanoma

FEATURING Minke Lucas
  • 24 views
  • October 14, 2024
10:07

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Sentinel Node (SN) Positive Melanoma With Minimal SN Tumor Burden - Primary Results of the EORTC 1208 Minitub Trial

FEATURING Alexander van Akkooi
  • 28 views
  • October 9, 2024
07:41

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: KEYNOTE-716 - Final Analysis of Distant Metastasis-Free Survival With Adjuvant Pembro vs. Placebo in Resected Stage IIB/IIC Melanoma

FEATURING Jason Luke
  • 23 views
  • October 7, 2024
10:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Predicting the Outcomes of Advanced Cutaneous Melanoma Cases Following Discontinuation of Immune Checkpoint Inhibition

FEATURING Ka-Won Noh, Oana Diana Persa
  • 65 views
  • October 3, 2024
11:25

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: CFT1946, a Novel BRAF V600X Degrader, in Preliminary Results in BRAF V600 Mutant Solid Tumors

FEATURING Maria Vieito
  • 26 views
  • September 20, 2024
09:22

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Nivo + Ipi ± ASTX727 in Anti-PD-1 Resistant Metastatic Melanoma - NIBIT-ML1 Ph2 Study

FEATURING Anna Maria Di Giacomo
  • 74 views
  • September 20, 2024
  • 1

Hematologic Oncology

757 views 65 hours watched
17:24

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Updates in the Treatment of MCL

FEATURING Georg Hess
  • 221 views
  • September 27, 2024
14:01

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in Heme Malignancies

FEATURING Maria Gomes da Silva
  • 419 views
  • September 23, 2024
  • 2
07:53

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: IDH Mutated Cholangiocarcinoma - Diagnostic and Treatment Paradigm

FEATURING Teresa Macarulla Mercade
  • 37 views
  • September 30, 2024
15:44

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Primary CNS Lymphoma - Updated ESMO and EHA Guidelines

FEATURING Andres Ferreri
  • 80 views
  • September 30, 2024

Sarcoma

209 views 24 hours watched
17:20

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights of Important Trials in Sarcoma

FEATURING Robin Jones
  • 179 views
  • October 9, 2024
10:56

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: MOTION Trial - Updated Efficacy & Safety of Vimseltinib in Patients With Tenosynovial Giant Cell Tumor

FEATURING Hans Gelderblom
  • 30 views
  • September 25, 2024